F
Francesco E. Pontieri
Researcher at Sapienza University of Rome
Publications - 140
Citations - 8326
Francesco E. Pontieri is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Parkinson's disease & Dopaminergic. The author has an hindex of 35, co-authored 128 publications receiving 7542 citations. Previous affiliations of Francesco E. Pontieri include National Institutes of Health & University of Cagliari.
Papers
More filters
Journal ArticleDOI
Dopaminergic system in peripheral blood mononuclear cells in Parkinson's disease.
Journal ArticleDOI
Cognitive and Neuropsychiatric Profiles in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinson's Disease.
Francesca Assogna,Claudio Liguori,Luca Cravello,Lucia Macchiusi,Claudia Belli,Fabio Placidi,Mariangela Pierantozzi,Alessandro Stefani,Bruno Mercuri,Francesca Izzi,Carlo Caltagirone,Nicola Biagio Mercuri,Francesco E. Pontieri,Gianfranco Spalletta,Clelia Pellicano +14 more
TL;DR: In this article, the authors compared neuropsychological and neuropsychiatric phenotypes of idiopathic (i) RBD, PD and healthy comparators (HC) in order to identify iRBD specific characteristics.
Journal ArticleDOI
Dopaminergic drug-induced modulation of the expression of the dopamine transporter in peripheral blood lymphocytes in Parkinson's disease.
Alessandra Fanciulli,Roberta Misasi,Dario Campanelli,Francesca R. Buttarelli,Francesco E. Pontieri +4 more
TL;DR: It is demonstrated that levodopa differs from dopamine agonists in its regulation of dopamine transporter expression in peripheral blood lymphocytes.
Journal ArticleDOI
The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
Angelo Antonini,Giovanni Abbruzzese,Alfredo Berardelli,Nicola Modugno,Italo Stroppa,Filippo Tamma,Mariachiara Sensi,Francesca Mancini,Giovanni Cossu,Alessandro Stefani,Nicola Tambasco,Alessandro Tessitore,Giovanni Fabbrini,Francesco E. Pontieri,Paolo Solla,Anna Rita Bentivoglio,Cristoforo Comi,Brigida Minafra,Giulio Riboldazzi,Donato Melchionda,Tommaso Martino,Leonardo Lopiano +21 more
TL;DR: LCIG after 12-month treatment led to sustained improvement of time spent in “OFF”, complications of therapy, PD-associated symptoms and sleep disorders, and LCIG tolerability was consistent with the established safety profile of LCIG.
Journal ArticleDOI
Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden
Nicola Modugno,Angelo Antonini,Alessandro Tessitore,Pietro Marano,Francesco E. Pontieri,Nicola Tambasco,Margherita Canesi,Giovanni Fabbrini,Mariachiara Sensi,Rocco Quatrale,Paolo Solla,Giovanni Defazio,Gabriella Melzi,Giuliana Gualberti,Leonardo Lopiano +14 more
TL;DR: Care partners of advanced PD patients treated with device-aided therapies have more time for their own life and a better perception of their QoL with a tendency to an improvement of mood compared with those of patients treating with CU.